RT Journal Article
SR Electronic
T1 Suppression of vitamin D metabolizing enzyme CYP24A1 provides increased sensitivity to chemotherapeutic drugs in breast cancer
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.10.18.512762
DO 10.1101/2022.10.18.512762
A1 Sakura Kamiya
A1 Nakamori Yuna
A1 Akira Takasawa
A1 Kumi Takasawa
A1 Daisuke Kyuno
A1 Yusuke Ono
A1 Kazufumi Magara
A1 Makoto Osanai
YR 2022
UL http://biorxiv.org/content/early/2022/10/21/2022.10.18.512762.abstract
AB Vitamin D is an essential nutrient for the human body that plays an important role in homeostasis and contributes to cell fate decision including proliferation, differentiation and cell viability. Accumulated epidemiological data suggest a relationship between vitamin D deficiency and carcinogenesis in various organs. However, the underlying mechanism remains to be further clarified. In this study, we showed that vitamin D metabolizing enzyme CYP24A1 promotes the oncogenic property of breast carcinoma cells. In addition, expression of CYP24A1 is elevated in invasive breast carcinoma and decreases the overall survival. Importantly, CYP24A1 suppression significantly enhances cell death sensitivity to two pharmacologically different acting anticancer drugs, cisplatin and gefitinib. The results of our study suggest the possibility of CYP24A1-inhibiting therapy for breast malignancy.Competing Interest StatementThe authors have declared no competing interest.